This new report focuses on a segment of cancer vaccine companies. It delivers advanced market profiling, interactive mindmaps, information about companies and investors, technology application use cases and other actionable information.

The current report version reviewed the cancer vaccine platforms: Neoantigen Platform, Tumor-associated Antigens Platform, Cellular Platform, and Oncolytic Viruses Platform — and the latest breakthrough and a potentially disruptive research strategy — Antigenic Essence Platform, which is actively developing its products to enter the market of immunotherapy. Additionally, we have added an entirely new chapter about cancer vaccine delivery systems, which is now a hot topic in biotechnology. As a result, we conducted an assessment of more than 390 investors, 150 companies and R&D centres and a detailed analysis of more than 30 of them.